OR2C1

Across TCGA pan-cancer cohorts, OR2C1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR2C1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher OR2C1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2C1 expression acts as an unfavorable survival marker.

UCS, STAD, and THCA are the cancer types where OR2C1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.007	0.689	<.001	24	view →
STAD	OS	Median	III,IV	0.075	0.633	<.001	22	view →
THCA	DFS	Median	All	0.070	0.896	<.001	18	view →
LUSC	DFS	Median	II,III,IV	0.505	0.749	.012	14	view →
COAD	DFS	Median	III,IV	0.005	0.668	<.001	12	view →
PRAD	DFS	Median	All	0.113	0.886	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR2C1–UCS (OS)

Open the UCS breakdown →